Open Veils · Answer
Could oral panacure c help this issue?
The off-label human use of fenbendazole — the active ingredient in Panacur C — has attracted serious attention from researchers and cancer survivors well outside veterinary circles. Joe Tippens' widely circulated self-reported remission from stage-4 small-cell lung cancer, documented through his 'My Cancer Story Rocks' blog, catalyzed a wave of anecdotal and investigational interest. South Korean oncologist Dr. Tae-hyun Yum published peer-reviewed case data corroborating antitumour effects, and researcher David Haase has discussed fenbendazole's multi-modal interference with cancer cell metabolism. The picture is compelling but still largely outside formal clinical trial confirmation.
Evidence
- Fenbendazole's mechanism as a potential anticancer compound rests on several proposed pathways documented by independent researchers.
- Joe Tippens, given weeks to live with stage-4 small-cell lung cancer in 2016, reported complete remission after self-administering fenbendazole alongside vitamin E succinate, CBD oil, and curcumin.
- Researcher and integrative oncology advocate Jane McLelland, author of 'How to Starve Cancer', places fenbendazole within a broader metabolic strategy targeting glucose and glutamine pathways.
- A critical transparency note: per thefenbendazole.com (April 2026), only 22.2% of each Panacur C sachet is actually fenbendazole — the remainder is lactose monohydrate, povidone K25, and maize starch, none listed on US packaging.
- According to work reviewed by Gregory Riggins at Johns Hopkins and discussed in the context of drug repurposing, fenbendazole disrupts tubulin polymerization in cancer cells — the same structural protein that many chemotherapy agents target — while appearing far less toxic to healthy tissue at therapeutic doses.